Literature DB >> 10813725

Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients.

P Bergh1, L G Kindblom, B Gunterberg, F Remotti, W Ryd, J M Meis-Kindblom.   

Abstract

BACKGROUND: The prognosis of patients with chordoma of the sacrum and mobile spine has been reported to be dismal and attributable in the majority of cases to intralesional surgery. The purpose of this study was to evaluate the clinical outcome of these patients using modern surgical principles aimed at complete resection and to identify prognostic factors.
METHODS: The clinical and morphologic features, type of surgery, and follow-up of 39 consecutive patients with chordoma were reviewed and analyzed statistically.
RESULTS: Thirty sacral and 9 mobile spine chordomas (size range, 3-20 cm; mean, 8 cm) occurring in 22 women and 17 men (median age, 55 years) were analyzed. The preoperative morphologic diagnosis was based on fine-needle aspiration (FNA) biopsy, core needle biopsy, or incisional biopsy. The final surgical margins were wide in 23 patients and marginal or intralesional in 16. The mean follow-up was 8.1 years (range, 0.1-23 years). Seventeen patients (44%) developed local recurrences and 11 patients (28%) developed metastases. The estimated 5-, 10-, 15-, and 20-year survival rates were 84%, 64%, 52%, and 52%, respectively. Local recurrence was associated significantly with an increased risk of metastasis and tumor-related death (P < 0.001).
CONCLUSIONS: New surgical techniques have improved local control and survival of patients with sacral or spinal chordoma significantly and have decreased progressive neurologic deterioration. Larger tumor size, performance of an invasive morphologic diagnostic procedure outside of the tumor center, inadequate surgical margins, microscopic tumor necrosis, Ki-67 > 5%, and local recurrence were found to be adverse prognostic factors. FNA is the preferred method for establishing the preoperative morphologic diagnosis of chordoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10813725     DOI: 10.1002/(sici)1097-0142(20000501)88:9<2122::aid-cncr19>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  137 in total

Review 1.  Management of metastatic sacral tumours.

Authors:  Nasir A Quraishi; Kyriakos E Giannoulis; Kimberley L Edwards; Bronek M Boszczyk
Journal:  Eur Spine J       Date:  2012-06-23       Impact factor: 3.134

2.  Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma.

Authors:  M Mima; Y Demizu; D Jin; N Hashimoto; M Takagi; K Terashima; O Fujii; Y Niwa; T Akagi; T Daimon; Y Hishikawa; M Abe; M Murakami; R Sasaki; N Fuwa
Journal:  Br J Radiol       Date:  2013-11-28       Impact factor: 3.039

3.  En bloc resection of a C4 chordoma: surgical technique.

Authors:  Yoseph Leitner; Shay Shabat; Luca Boriani; Stefano Boriani
Journal:  Eur Spine J       Date:  2007-08-23       Impact factor: 3.134

4.  Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival.

Authors:  Chetan Bettegowda; Stephen Yip; Sheng-Fu Larry Lo; Charles G Fisher; Stefano Boriani; Laurence D Rhines; Joanna Y Wang; Aron Lazary; Marco Gambarotti; Wei-Lien Wang; Alessandro Luzzati; Mark B Dekutoski; Mark H Bilsky; Dean Chou; Michael G Fehlings; Edward F McCarthy; Nasir A Quraishi; Jeremy J Reynolds; Daniel M Sciubba; Richard P Williams; Jean-Paul Wolinsky; Patricia L Zadnik; Ming Zhang; Niccole M Germscheid; Vasiliki Kalampoki; Peter Pal Varga; Ziya L Gokaslan
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

5.  Image-guided percutaneous lipiodol-pingyangmycin suspension injection therapy for sacral chordoma.

Authors:  Dexiao Huang; Yong Chen; Qingle Zeng; Renhua Wu; Yanhao Li
Journal:  Korean J Radiol       Date:  2013-08-30       Impact factor: 3.500

6.  UM-Chor1: establishment and characterization of the first validated clival chordoma cell line.

Authors:  John Henry Owen; Christine M Komarck; Anthony C Wang; Waleed M Abuzeid; Richard F Keep; Erin L McKean; Stephen Sullivan; Xing Fan; Mark E P Prince
Journal:  J Neurosurg       Date:  2017-04-21       Impact factor: 5.115

7.  Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center.

Authors:  Tong Meng; Huabin Yin; Bo Li; Zhenxi Li; Wei Xu; Wang Zhou; Mo Cheng; Jing Wang; Lei Zhou; Xinghai Yang; Tielong Liu; Wangjun Yan; Dianwen Song; Jianru Xiao
Journal:  Neuro Oncol       Date:  2014-12-08       Impact factor: 12.300

8.  Metastatic disease from chordoma.

Authors:  Gloria Vergara; Belén Belinchón; Francisco Valcárcel; María Veiras; Irma Zapata; Alejandro de la Torre
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

Review 9.  Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma.

Authors:  Brian J Jian; Orin G Bloch; Isaac Yang; Seunggu J Han; Derick Aranda; Tarik Tihan; Andrew T Parsa
Journal:  J Neurooncol       Date:  2009-12-02       Impact factor: 4.130

10.  The rare case of giant cell tumor occuring in the axial skeleton after 15 years of follow-up: Case report.

Authors:  Ye-Soo Park; Jin Kyu Lee; Seung-Wook Baek; Chan-Kum Park
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.